Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Cost-Effectiveness Analysis of Mitral Valve Repair With the Mitraclip Delivery System for Patients With Mitral Regurgitation: A Systematic Review Publisher Pubmed



Rezapour A1 ; Azari S1, 2 ; Arabloo J1 ; Pourasghari H2 ; Behzadifar M3 ; Alipour V1 ; Omidi N4 ; Sadeghian S5 ; Aghajani H5 ; Bragazzi NL6
Authors
Show Affiliations
Authors Affiliations
  1. 1. Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran
  2. 2. Hospital Management Research Center, Iran University of Medical Sciences, Tehran, Iran
  3. 3. Social Determinants of Health Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran
  4. 4. Department of Cardiology, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Department of Interventional Cardiology, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran
  6. 6. Laboratory for Industrial and Applied Mathematics (LIAM), Department of Mathematics and Statistics, York University, Toronto, Canada

Source: Heart Failure Reviews Published:2021


Abstract

To assess the cost-effectiveness of mitral valve repair with the MitraClip delivery system for patients with mitral regurgitation and heart failure, a systematic literature search was conducted in various electronic databases to January 3, 2020. Eligibility criteria are the population (patients with mitral regurgitation (MR)), intervention (transcatheter mitral valve repair using the MitraClip), comparator (conventional medical treatment), outcomes, and designs (Model-based or trial-based full economic evaluations).The quality of included studies was assessed using the CHEERS checklist. Mortality and survival rate, quality-adjusted life year (QALY), life years gained (LYG), total cost, and the incremental cost-effectiveness ratio (ICER) regarding the use of MitraClip System were considered as the key outcomes. Eight articles were eligible for full-text assessment. Ultimately, a total of seven studies were considered in the current systematic review. Results demonstrated that MitraClip reduces mortality rate and increases survival rate. The mortality rate at 1 year and 10 years was 16.7% versus 29.77% and 70.9% versus 98.8%, respectively. Total cost data based on 2019 USD show that the MitraClip has the highest cost in the USA ($121,390) and the lowest cost in Italy ($33,062). The results showed that in all selected countries, willingness-to-pay (WTP) thresholds are upper than the cost per QALY; also, the highest ICER for the MitraClip is in the USA ($55,600/QALY) and the lowest in Italy ($10,616/QALY). To conclude, evidence from this systematic review suggests that MitraClip Delivery System improved both life expectancy and QALY compared with medical treatment in patients at high surgical risk and it was also a cost-effective treatment option for patients with mitral regurgitation. © 2020, Springer Science+Business Media, LLC, part of Springer Nature.